University of Queensland, Ultragenyx deal
The UniQuest Pty. Ltd. commercialization arm of the University of Queensland granted Ultragenyx exclusive, worldwide rights to IP related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with Ultragenyx's triheptanoin ( UX007). The company declined to disclose financial terms. Triheptanoin is in Phase II trials to treat long-chain fatty acid oxidation disorders and to treat glucose transporter type-1 deficiency syndrome in patients who have failed a ketogenic diet and continue to have breakthrough seizures. Interim data from both trials are expected next year. The product is a synthetic compound that provides medium-length, odd-chain fatty acids that are metabolized to replace intermediate substrates in fatty acid oxidation and in the tricarboxylic acid (TCA) cycle. ...